Sponsored by ?

This article was paid for by a contributing third party.More Information.

The optimisation of everything: OTC derivatives, counterparty risk and funding

Content provided by IBM

159292670

As banks become more sensitive to capital and funding costs under Basel III, traders need smarter analytics to price factors related to capital, counterparty risk and collateral

The global financial crisis has created much excitement around counterparty credit risk (CCR) and, in recognition of this, banks have been improving their practices around CCR.

In particular, the use of credit value adjustment (CVA) to facilitate pricing and management of CCR has increased significantly. Indeed, many banks have CVA desks that are responsible for pricing and managing CVA across trading functions.

In addition to CVA, debt value adjustment (DVA) is often used as recognition of the 'benefit' arising from one's own default and funding aspects may be considered via funding value adjustment (FVA). Also, the impact that collateral has on CVA, DVA and FVA is important to quantify.

Finally, there is a need to consider the impact of the funding requirements and systemic risk when trading with central counterparties (CCPs).

Read/download the white paper

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here